Miniatura

Fitxers

258010.pdf (683.82 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2022-06-14

Llicència de publicació

cc-by-nc (c) Erton ZB et al., 2022
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/207749

Pregnancy outcomes in antiphospholipid antibody positive patients: prospective results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository ('Registry').

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1136/lupus-2021-000633

Resum

Objectives: To describe the outcomes of pregnancies in antiphospholipid antibody (aPL)-positive patients since the inception of the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking Registry. Methods: We identified persistently aPL-positive patients recorded as 'pregnant' during prospective follow-up, and defined 'aPL-related outcome' as a composite of: (1) Preterm live delivery (PTLD) at or before 37th week due to pre-eclampsia (PEC), eclampsia, small-for-gestational age (SGA) and/or placental insufficiency (PI); or (2) Otherwise unexplained fetal death after the 10th week of gestation. The primary objective was to describe the characteristics of patients with and without aPL-related composite outcomes based on their first observed pregnancies following registry recruitment. Results: Of the 55 first pregnancies observed after registry recruitment among nulliparous and multiparous participants, 15 (27%) resulted in early pregnancy loss <10 weeks gestation. Of the remaining 40 pregnancies: (1) 26 (65%) resulted in term live delivery (TLD), 4 (10%) in PTLD between 34.0 weeks and 36.6 weeks, 5 (12.5%) in PTLD before 34th week, and 5 (12.5%) in fetal death (two associated with genetic anomalies); and (2) The aPL-related composite outcome occurred in 9 (23%). One of 26 (4%) pregnancies with TLD, 3/4 (75%) with PTLD between 34.0 weeks and 36.6 weeks, and 3/5 (60%) with PTLD before 34th week were complicated with PEC, SGA and/or PI. Fifty of 55 (91%) pregnancies were in lupus anticoagulant positive subjects, as well as all pregnancies with aPL-related composite outcome. Conclusion: In our multicentre, international, aPL-positive cohort, of 55 first pregnancies observed prospectively, 15 (27%) were complicated by early pregnancy loss. Of the remaining 40 pregnancies, composite pregnancy morbidity was observed in 9 (23%) pregnancies.

Matèries

Embaràs, Mort del fetus, Avortament, Lupus eritematós, Síndrome antifosfolipídica, Assaigs clínics

Matèries (anglès)

Pregnancy, Fetal death, Abortion, Lupus erythematosus, Antiphospholipid syndrome, Clinical trials

Citació

Col·leccions

Articles publicats en revistes (Medicina)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Citació

ERTON, Zeynep belce, SEVIM, Ecem, DE JESÚS, Guilherme ramires, CERVERA I SEGURA, Ricard, JI, Lan lan, PENGO, Vittorio, UGARTE, Amaia, ANDRADE, Danieli, ANDREOLI, Laura, ATSUMI, Tatsuya, FORTIN, Paul r., GEROSA, Maria, ZUO, Yu, PETRI, Michelle a., SCIASCIA, Savino, TEKTONIDOU, Maria, AGUIRRE ZAMORANO, Mª. ángeles, BRANCH, D ware, ERKAN, Doruk. Pregnancy outcomes in antiphospholipid antibody positive patients: prospective results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository ('Registry').. _Lupus Science & Medicine_. 2022. Vol. 9, núm. 1, pàgs. e000633. [consulta: 24 de gener de 2026]. ISSN: 2053-8790. [Disponible a: https://hdl.handle.net/2445/207749]

Exportar metadades

JSON - METS

Compartir registre